Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Palatin Technologies Inc (PTN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Palatin's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.8600 +0.0700    +3.91%
03:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
1.8700
+0.0100
+0.5376%
5:12:49 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 147,377
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 1.7900 - 1.9300
Palatin 1.8600 +0.0700 +3.91%

Palatin Technologies Inc Company Profile

 
Get an in-depth profile of Palatin Technologies Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

33

Equity Type

ORD

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

Contact Information

Address Cedar Brook Corporate Center 4-B Cedar Brook Drive
Cranbury, 08512
United States
Phone 609 495 2200
Fax 609 495 2202

Top Executives

Name Age Since Title
J. Stanley Hull 70 2005 Independent Director
Robert K. deVeer 76 1998 Independent Director
Carl Spana 60 1996 Co-Founder, President, CEO & Director
John K. A. Prendergast 68 1996 Independent Non-Executive Chairman
Alan W. Dunton 68 2011 Independent Director
Michael A. Perelman - - Member of Female Sexual Dysfunction Expert Panel
Raymond C. Rosen - - Member of Female Sexual Dysfunction Expert Panel
James Pfaus - - Member of Female Sexual Dysfunction Expert Panel
Murray Freedman - - Member of Female Sexual Dysfunction Healthcare Provider Expert Panel
Lisa Larkin - - Member of Female Sexual Dysfunction Healthcare Provider Expert Panel
Arlene M. Morris 70 2015 Independent Director
Stanley E. Althof - - Member of Female Sexual Dysfunction Expert Panel
Sharon J. Parish - - Member of Female Sexual Dysfunction Expert Panel
Ricki Pollycove 67 - Member of Female Sexual Dysfunction Healthcare Provider Expert Panel
Risa Kagan - - Member of Female Sexual Dysfunction Healthcare Provider Expert Panel
Martin Miner - - Member of Female Sexual Dysfunction Healthcare Provider Expert Panel
Anthony M. Manning 60 2017 Independent Director
Brooke M. Faught - - Member of Female Sexual Dysfunction Healthcare Provider Expert Panel
Anita H. Clayton - - Member of Female Sexual Dysfunction Expert Panel
Sheryl A. Kingsberg - - Member of Female Sexual Dysfunction Expert Panel
Susan G. Kornstein - - Member of Female Sexual Dysfunction Healthcare Provider Expert Panel
Cindy M. Meston - - Member of Female Sexual Dysfunction Expert Panel
Susan Kellogg-Spadt - - Member of Female Sexual Dysfunction Healthcare Provider Expert Panel
Leonard R. Derogatis - - Member of Female Sexual Dysfunction Expert Panel
Robin Kroll - - Member of Female Sexual Dysfunction Healthcare Provider Expert Panel
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PTN Comments

Write your thoughts about Palatin Technologies Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email